ArticleThe journal of pathology. Clinical research2026
A membranous nephropathy variant mimicking minimal change disease.
Article in The journal of pathology. Clinical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study characterizes a novel disease pattern of membranous nephropathy (MN) that exhibits overlapping clinicopathological features with minimal change disease (MCD), termed 'MCD-like MN'. Patients with histologically confirmed MN showing sparse and segmental subepithelial electron-dense deposits (EDD) but clinically resembling MCD were enrolled, alongside age- and gender-matched classic MCD and MN controls. Clinicopathological parameters were compared across groups. MN-associated antigens and MCD-related podocyte antigens were analyzed in renal tissues and serum. Among 107 archival MCD cases re-evaluated, 16 were reclassified as MCD-like MN based on EDD presence. Pathologically, these cases demonstrated IgG deposition in podocytes (62.5%), significantly higher than classic MCD (6.2%), but lacked complement activation and showed milder interstitial fibrosis compared to MN. Clinically, MCD-like MN patients presented a shorter disease duration and higher complete remission rates compared to MN (p < 0.01), resembling classical MCD. Additionally, they had lower serum creatinine levels than MCD patients (p < 0.01), which were more similar to MN levels. Furthermore, MN-associated antigens were detected in MCD-like MN cases and some of the serum antibodies' levels were increased, suggesting shared pathogenesis with MN, albeit with distinct immune features. Besides, spectrometry counts of podocyte antigens were not increased, and serum anti-podocyte antibodies were either absent or not elevated compared to MCD patients, ruling out antibody-mediated podocytopathy. Collectively, MCD-like MN represents a distinct MN subtype with atypical MCD-like clinicopathological features, likely driven by a unique immune mechanism divergent from both classic MN and MCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.